Table 3.
Changes in health-related quality of life, patient functioning and disability scores during post-treatment period from Month 12 to Month 14 and Month 16
| Baselinea | Month 14b | Month 16b | ||||
|---|---|---|---|---|---|---|
| GMB 120 mg N = 106 |
GMB 240 mg N = 118 |
GMB 120 mg N = 100 |
GMB 240 mg N = 113 |
GMB 120 mg N = 99 |
GMB 240 mg N = 115 |
|
| MSQv2.1 total | ||||||
| Month 12 mean (SD) score | 83.7 (18.9) | 87.3 (15.5) | ||||
| LS mean change (SE) | − 7.1 (1.7) | − 8.4 (1.6) | − 8.1 (1.8) | − 9.6 (1.7) | ||
| Diff vs 120 mg (SE) | – | − 1.3 (2.2) | – | − 1.6 (2.4) | ||
| 95% CI | – | − 5.7, 3.1 | – | − 6.3, 3.2 | ||
| RF-R | ||||||
| Month 12 mean (SD) score | 80.6 (20.3) | 84.7 (16.4) | ||||
| LS mean change (SE) | − 7.1 (1.8) | − 9.5 (1.7) | − 8.7 (1.9) | − 10.3 (1.7) | ||
| Diff vs 120 mg (SE) | – | − 2.4 (2.4) | – | − 1.6 (2.5) | ||
| 95% CI | – | − 7.1, 2.3 | – | − 6.5, 3.3 | ||
| RF-P | ||||||
| Month 12 mean (SD) score | 87.7 (16.7) | 89.9 (14.8) | ||||
| LS Mean change (SE) | − 5.6 (1.6) | − 6.7 (1.5) | − 6.6 (1.7) | − 8.2 (1.6) | ||
| Diff vs 120 mg (SE) | – | − 1.1 (2.2) | – | − 1.6 (2.3) | ||
| 95% CI | – | − 5.4, 3.2 | – | − 6.1, 2.9 | ||
| EF | ||||||
| Month 12 mean (SD) score | 85.5 (22.0) | 90.1 (17.3) | ||||
| LS mean change (SE) | − 9.1 (2.0) | − 7.8 (1.9) | − 8.4 (2.2) | − 9.9 (2.0) | ||
| Diff vs 120 mg (SE) | – | 1.4 (2.7) | − 1.5 (2.9) | |||
| 95% CI | – | − 3.9, 6.6 | – | − 7.2, 4.2 | ||
| MIDAS total | ||||||
| Month 12 mean (SD) score | 15.4 (31.6) | 16.1 (32.5) | ||||
| LS Mean change (SE) | – | – | 7.3 (3.8) | 11.8 (3.4) | ||
| Diff vs 120 mg (SE) | – | – | – | 4.5 (4.8) | ||
| 95% CI | – | – | – | − 5.1, 14.0 | ||
Patients did not receive any study medication during this period
EF emotional function; GMB galcanezumab; MIDAS migraine disability assessment; MSQv2.1 migraine-specific quality of life questionnaire version 2.1; RF-P role function-preventive; RF-R role function-restrictive; SD standard deviation; SE standard error
aBaseline is the last visit of treatment phase (Month 12)
bAll p-values (within-group improvement) for MSQ total and domain scores < 0.001